Marjanka K Schmidt

List of Publications by Year in Descending Order

272 papers	16,284 citations	64 h-index	121 g-index
306 ext. papers	19,936 ext. citations	9 avg, IF	5.21 L-index

#	Paper	IF	Citations
272	Rare germline copy number variants (CNVs) and breast cancer risk.. *Communications Biology*, **2022**, 5, 65	6.7	0
271	Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial.. *Journal of Clinical Oncology*, **2022**, JCO2102019	2.2	4
270	Common variants in breast cancer risk loci predispose to distinct tumor subtypes.. *Breast Cancer Research*, **2022**, 24, 2	8.3	3
269	Pathology of Tumors Associated With Pathogenic Germline Variants in 9 Breast Cancer Susceptibility Genes.. *JAMA Oncology*, **2022**,	13.4	4
268	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy.. *Journal of Clinical Oncology*, **2022**, JCO2101536	2.2	2
267	Towards implementation of comprehensive breast cancer risk prediction tools in health care for personalised prevention.. *Preventive Medicine*, **2022**, 107075	4.3	0
266	Breast cancer risks associated with missense variants in breast cancer susceptibility genes.. *Genome Medicine*, **2022**, 14, 51	14.4	0
265	Germline breast cancer susceptibility genes, tumor characteristics, and survival. *Genome Medicine*, **2021**, 13, 185	14.4	0
264	Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial. *Annals of Oncology*, **2021**,	10.3	1
263	Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study.. *Breast*, **2021**, 61, 98-107	3.6	0
262	Germline variants and breast cancer survival in patients with distant metastases at primary breast cancer diagnosis. *Scientific Reports*, **2021**, 11, 19787	4.9	0
261	Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation Carriers. *Journal of the National Cancer Institute*, **2021**, 113, 893-899	9.7	4
260	Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. *International Journal of Epidemiology*, **2021**,	7.8	6
259	Evaluation of the association of heterozygous germline variants in NTHL1 with breast cancer predisposition: an international multi-center study of 47,180 subjects. *Npj Breast Cancer*, **2021**, 7, 52	7.8	2
258	Letter to the editor regarding: 'Association between BRCA mutational status and survival in patients with breast cancer: a systematic review and meta-analysis'. *Breast Cancer Research and Treatment*, **2021**, 188, 821-823	4.4	0
257	Combining method of detection and 70-gene signature for enhanced prognostication of breast cancer. *Breast Cancer Research and Treatment*, **2021**, 189, 399-410	4.4	2
256	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. *Genetics in Medicine*, **2021**, 23, 1726-1737	8.1	2

255	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. *American Journal of Human Genetics*, **2021**, 108, 1190-1203	11	1
254	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. *Journal of the National Cancer Institute*, **2021**, 113, 329-337	9.7	14
253	Comprehensive trends in incidence, treatment, survival and mortality of first primary invasive breast cancer stratified by age, stage and receptor subtype in the Netherlands between 1989 and 2017. *International Journal of Cancer*, **2021**, 148, 2289-2303	7.5	7
252	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. *British Journal of Cancer*, **2021**, 124, 842-854	8.7	2
251	Browser-based Data Annotation, Active Learning, and Real-Time Distribution of Artificial Intelligence Models: From Tumor Tissue Microarrays to COVID-19 Radiology. *Journal of Pathology Informatics*, **2021**, 12, 38	4.4	0
250	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. *Nature Communications*, **2021**, 12, 1078	17.4	4
249	Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. *New England Journal of Medicine*, **2021**, 384, 428-439	59.2	143
248	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. *Breast Cancer Research*, **2021**, 23, 86	8.3	1
247	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. *British Journal of Cancer*, **2021**, 125, 1135-1145	8.7	0
246	Genetic insights into biological mechanisms governing human ovarian ageing. *Nature*, **2021**, 596, 393-397	50.4	28
245	Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast. *British Journal of Cancer*, **2021**, 125, 1443-1449	8.7	1
244	Circadian PERformance in breast cancer: a germline and somatic genetic study of PER3 polymorphisms and gene co-expression. *Npj Breast Cancer*, **2021**, 7, 118	7.8	1
243	Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2021**, 30, 623-642	4	4
242	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nature Genetics*, **2020**, 52, 572-581	36.3	76
241	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. *Nature Reviews Clinical Oncology*, **2020**, 17, 687-705	19.4	64
240	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. *Scientific Reports*, **2020**, 10, 9688	4.9	2
239	Variants of uncertain clinical significance in hereditary breast and ovarian cancer genes: best practices in functional analysis for clinical annotation. *Journal of Medical Genetics*, **2020**, 57, 509-518	5.8	14
238	Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort. *Genetics in Medicine*, **2020**, 22, 1803-1811	8.1	17

237	Assessment of polygenic architecture and risk prediction based on common variants across fourteen cancers. *Nature Communications*, **2020**, 11, 3353	17.4	32
236	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genetic Epidemiology*, **2020**, 44, 442-468	2.6	9
235	The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review. *Breast*, **2020**, 50, 95-103	3.6	1
234	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. *Nature Communications*, **2020**, 11, 312	17.4	20
233	Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. *Breast Cancer Research and Treatment*, **2020**, 181, 423-434	4.4	7
232	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73	36.3	56
231	A Mendelian randomization analysis of circulating lipid traits and breast cancer risk. *International Journal of Epidemiology*, **2020**, 49, 1117-1131	7.8	17
230	The prognostic value of the tumor-stroma ratio is most discriminative in patients with grade III or triple-negative breast cancer. *International Journal of Cancer*, **2020**, 146, 2296-2304	7.5	18
229	Breast cancer risk factors and their effects on survival: a Mendelian randomisation study. *BMC Medicine*, **2020**, 18, 327	11.4	7
228	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. *American Journal of Human Genetics*, **2020**, 107, 837-848	11	12
227	Association of germline variation with the survival of women with pathogenic variants and breast cancer. *Npj Breast Cancer*, **2020**, 6, 44	7.8	3
226	Contralateral breast cancer risk in patients with ductal carcinoma in situ and invasive breast cancer. *Npj Breast Cancer*, **2020**, 6, 60	7.8	0
225	Assessment of interactions between 205 breast cancer susceptibility loci and 13 established risk factors in relation to breast cancer risk, in the Breast Cancer Association Consortium. *International Journal of Epidemiology*, **2020**, 49, 216-232	7.8	13
224	Re-evaluating genetic variants identified in candidate gene studies of breast cancer risk using data from nearly 280,000 women of Asian and European ancestry. *EBioMedicine*, **2019**, 48, 203-211	8.8	9
223	Two truncating variants in FANCC and breast cancer risk. *Scientific Reports*, **2019**, 9, 12524	4.9	2
222	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019**, 10, 431	17.4	45
221	The Influence of Adjuvant Systemic Regimens on Contralateral Breast Cancer Risk and Receptor Subtype. *Journal of the National Cancer Institute*, **2019**, 111, 709-718	9.7	27
220	Type 2 Diabetes, but Not Insulin (Analog) Treatment, Is Associated With More Advanced Stages of Breast Cancer: A National Linkage of Cancer and Pharmacy Registries. *Diabetes Care*, **2019**, 42, 434-442	14.6	8

219	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nature Communications*, **2019**, 10, 1741	17.4	47
218	Predictors of an Invasive Breast Cancer Recurrence after DCIS: A Systematic Review and Meta-analyses. *Cancer Epidemiology Biomarkers and Prevention*, **2019**, 28, 835-845	4	17
217	Genome-wide association study of germline variants and breast cancer-specific mortality. *British Journal of Cancer*, **2019**, 120, 647-657	8.7	28
216	Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients. *Annals of Surgery*, **2019**, 270, 364-372	7.8	24
215	Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. *Breast Cancer Research*, **2019**, 21, 90	8.3	45
214	Breast Cancer Susceptibility□owards Individualised Risk Prediction. *Current Genetic Medicine Reports*, **2019**, 7, 124-135	2.2	3
213	The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. *Npj Breast Cancer*, **2019**, 5, 38	7.8	12
212	A response to "Personalised medicine and population health: breast and ovarian cancer". *Human Genetics*, **2019**, 138, 287-289	6.3	13
211	Discordant Marker Expression Between Invasive Breast Carcinoma and Corresponding Synchronous and Preceding DCIS. *American Journal of Surgical Pathology*, **2019**, 43, 1574-1582	6.7	13
210	Prediction and clinical utility of a contralateral breast cancer risk model. *Breast Cancer Research*, **2019**, 21, 144	8.3	11
209	Risk factors for metachronous contralateral breast cancer: A systematic review and meta-analysis. *Breast*, **2019**, 44, 1-14	3.6	25
208	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. *American Journal of Human Genetics*, **2019**, 104, 21-34	11	363
207	Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma. *Blood*, **2019**, 133, 1130-1139	2.2	17
206	BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. *Genetics in Medicine*, **2019**, 21, 1708-1718	8.1	192
205	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. *International Journal of Epidemiology*, **2019**, 48, 795-806	7.8	52
204	Clinicians' use of breast cancer risk assessment tools according to their perceived importance of breast cancer risk factors: an international survey. *Journal of Community Genetics*, **2019**, 10, 61-71	2.5	5
203	The BRCA2 c.68-7T□□A variant is not pathogenic: A model for clinical calibration of spliceogenicity. *Human Mutation*, **2018**, 39, 729-741	4.7	16
202	Patients' Attitudes Towards the Return of Incidental Findings After Research with Residual Tissue: A Mixed Methods Study. *Genetic Testing and Molecular Biomarkers*, **2018**, 22, 178-186	1.6	5

201	Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation. *International Journal of Cancer*, **2018**, 143, 746-757	7.5	9
200	Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma -A Nested Case-Control Study. *Clinical Cancer Research*, **2018**, 24, 3593-3601	12.9	23
199	Joint associations of a polygenic risk score and environmental risk factors for breast cancer in the Breast Cancer Association Consortium. *International Journal of Epidemiology*, **2018**, 47, 526-536	7.8	53
198	E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. *Scientific Reports*, **2018**, 8, 6574	4.9	19
197	Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ. *Annals of Surgery*, **2018**, 267, 952-958	7.8	31
196	Breast cancer-related deaths according to grade in ductal carcinoma in situ: A Dutch population-based study on patients diagnosed between 1999 and 2012. *European Journal of Cancer* , **2018**, 101, 134-142	7.5	11
195	The association of diabetes mellitus and insulin treatment with expression of insulin-related proteins in breast tumors. *BMC Cancer*, **2018**, 18, 224	4.8	6
194	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. *Nature Genetics*, **2018**, 50, 968-978	36.3	101
193	Recall and Retention of Consent Procedure Contents and Decisions: Results of a Randomized Controlled Trial. *Public Health Genomics*, **2018**, 21, 27-36	1.9	1
192	Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, -like status, tumor-infiltrating immune cells and survival. *OncoImmunology*, **2018**, 7, e1509820	7.2	51
191	Exploring the role of low-frequency and rare exonic variants in alcohol and tobacco use. *Drug and Alcohol Dependence*, **2018**, 188, 94-101	4.9	7
190	Rare and low-frequency coding variants alter human adult height. *Nature*, **2017**, 542, 186-190	50.4	412
189	An association study of established breast cancer reproductive and lifestyle risk factors with tumour subtype defined by the prognostic 70-gene expression signature (MammaPrint). *European Journal of Cancer*, **2017**, 75, 5-13	7.5	10
188	Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. *Cancer Research*, **2017**, 77, 2789-2799	10.1	49
187	Trends in breast cancer incidence among women with type-2 diabetes in British general practice. *Primary Care Diabetes*, **2017**, 11, 373-382	2.4	7
186	Genomic analyses identify hundreds of variants associated with age at menarche and support a role for puberty timing in cancer risk. *Nature Genetics*, **2017**, 49, 834-841	36.3	257
185	Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years. *European Journal of Cancer*, **2017**, 78, 37-44	7.5	22
184	Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	40

183	Cancer risk among insulin users: comparing analogues with human insulin in the CARING five-country cohort study. *Diabetologia*, **2017**, 60, 1691-1703	10.3	41
182	Association analysis identifies 65 new breast cancer risk loci. *Nature*, **2017**, 551, 92-94	50.4	643
181	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
180	Diabetes and Breast Cancer Subtypes. *PLoS ONE*, **2017**, 12, e0170084	3.7	29
179	Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study. *Breast Cancer Research*, **2017**, 19, 119	8.3	26
178	The prognostic value of the tumour-stroma ratio in primary operable invasive cancer of the breast: a validation study. *Breast Cancer Research and Treatment*, **2017**, 166, 435-445	4.4	25
177	Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium. *International Journal of Cancer*, **2017**, 141, 1830-1840	7.5	13
176	Long-term prognosis of young breast cancer patients (≤40 years) who did not receive adjuvant systemic treatment: protocol for the PARADIGM initiative cohort study. *BMJ Open*, **2017**, 7, e017842	3	7
175	The role of Indonesian patients' health behaviors in delaying the diagnosis of nasopharyngeal carcinoma. *BMC Public Health*, **2017**, 17, 510	4.1	12
174	The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study. *Breast Cancer Research*, **2017**, 19, 26	8.3	9
173	An updated PREDICT breast cancer prognostication and treatment benefit prediction model with independent validation. *Breast Cancer Research*, **2017**, 19, 58	8.3	100
172	Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. *Genetics in Medicine*, **2017**, 19, 599-603	6.3	51
171	Body mass index and breast cancer survival: a Mendelian randomization analysis. *International Journal of Epidemiology*, **2017**, 46, 1814-1822	7.8	27
170	Evaluation of the EGFR polymorphism R497K in two cohorts of neoadjuvantly treated breast cancer patients. *PLoS ONE*, **2017**, 12, e0189750	3.7	3
169	TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer. *Oncotarget*, **2017**, 8, 18381-18398	3.3	7
168	- a novel candidate breast cancer susceptibility locus on 6q14.1. *Oncotarget*, **2017**, 8, 102769-102782	3.3	3
167	Independent replication of polymorphisms predicting toxicity in breast cancer patients randomized between dose-dense and docetaxel-containing adjuvant chemotherapy. *Oncotarget*, **2017**, 8, 113531-113542	3.3	6
166	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15

165	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. *Human Molecular Genetics*, **2016**, 25, 3863-3876	5.6	24
164	rs2735383, located at a microRNA binding site in the 3'UTR of NBS1, is not associated with breast cancer risk. *Scientific Reports*, **2016**, 6, 36874	4.9	2
163	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. *Cancer Discovery*, **2016**, 6, 1052-67	24.4	104
162	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nature Communications*, **2016**, 7, 11375	17.4	64
161	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
160	Fine scale mapping of the 17q22 breast cancer locus using dense SNPs, genotyped within the Collaborative Oncological Gene-Environment Study (COGs). *Scientific Reports*, **2016**, 6, 32512	4.9	16
159	Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. *Breast Cancer Research*, **2016**, 18, 104	8.3	44
158	Effectiveness of a multicentre nasopharyngeal carcinoma awareness programme in Indonesia. *BMJ Open*, **2016**, 6, e008571	3	2
157	Age- and Tumor Subtype-Specific Breast Cancer Risk Estimates for CHEK2*1100delC Carriers. *Journal of Clinical Oncology*, **2016**, 34, 2750-60	2.2	107
156	Exceptions to the rule of informed consent for research with an intervention. *BMC Medical Ethics*, **2016**, 17, 9	2.9	31
155	Gene-environment interaction and risk of breast cancer. *British Journal of Cancer*, **2016**, 114, 125-33	8.7	108
154	High-throughput automated scoring of Ki67 in breast cancer tissue microarrays from the Breast Cancer Association Consortium. *Journal of Pathology: Clinical Research*, **2016**, 2, 138-53	5.3	16
153	No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing. *Journal of Medical Genetics*, **2016**, 53, 298-309	5.8	83
152	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nature Genetics*, **2016**, 48, 374-86	36.3	93
151	Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers. *British Journal of Cancer*, **2016**, 114, 298-304	8.7	5
150	Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers. *Journal of Clinical Oncology*, **2016**, 34, 409-18	2.2	65
149	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. *Human Genetics*, **2016**, 135, 137-54	6.3	6
148	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	65

147	Abstract 2030: The role of genetic variation in calcium-activated potassium channels in breast cancer patients treated with tamoxifen **2016**,		2
146	The Impact of the Overall Radiotherapy Time on Clinical Outcome of Patients with Nasopharyngeal Carcinoma; A Retrospective Study. *PLoS ONE*, **2016**, 11, e0151899	3.7	9
145	A Randomised Controlled Trial of Consent Procedures for the Use of Residual Tissues for Medical Research: Preferences of and Implications for Patients, Research and Clinical Practice. *PLoS ONE*, **2016**, 11, e0152509	3.7	4
144	RAD51B in Familial Breast Cancer. *PLoS ONE*, **2016**, 11, e0153788	3.7	18
143	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. *Oncotarget*, **2016**, 7, 80140-80163	3.3	21
142	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. *PLoS Medicine*, **2016**, 13, e1002105	11.6	80
141	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. *PLoS ONE*, **2016**, 11, e0160316	3.7	11
140	Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. *International Journal of Cancer*, **2016**, 139, 1303-1317	7.5	26
139	PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. *Journal of Medical Genetics*, **2016**, 53, 800-811	5.8	121
138	Recurrent HOXB13 mutations in the Dutch population do not associate with increased breast cancer risk. *Scientific Reports*, **2016**, 6, 30026	4.9	1
137	Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women. *Breast Cancer Research and Treatment*, **2016**, 159, 553-63	4.4	34
136	Patient survival and tumor characteristics associated with CHEK2:p.I157T - findings from the Breast Cancer Association Consortium. *Breast Cancer Research*, **2016**, 18, 98	8.3	26
135	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Research*, **2016**, 18, 64	8.3	25
134	Genetic predisposition to ductal carcinoma in situ of the breast. *Breast Cancer Research*, **2016**, 18, 22	8.3	31
133	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. *Cancer Causes and Control*, **2016**, 27, 679-93	2.8	15
132	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. *American Journal of Human Genetics*, **2016**, 99, 903-911	11	43
131	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. *Carcinogenesis*, **2015**, 36, 256-71	4.6	12
130	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. *Nature Genetics*, **2015**, 47, 373-80	36.3	406

129	Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study. *Familial Cancer*, **2015**, 14, 355-63	3	11
128	Evaluation of the Dutch BRCA1/2 clinical genetic center referral criteria in an unselected early breast cancer population. *European Journal of Human Genetics*, **2015**, 23, 588-95	5.3	12
127	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. *American Journal of Human Genetics*, **2015**, 97, 22-34	11	26
126	Identification of novel genetic markers of breast cancer survival. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	38
125	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with prognosis of estrogen receptor-negative breast cancer after chemotherapy. *Breast Cancer Research*, **2015**, 17, 18	8.3	17
124	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. *Nature Genetics*, **2015**, 47, 1294-1303	36.3	226
123	Annexin A1 expression in a pooled breast cancer series: association with tumor subtypes and prognosis. *BMC Medicine*, **2015**, 13, 156	11.4	37
122	Height and Breast Cancer Risk: Evidence From Prospective Studies and Mendelian Randomization. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	74
121	Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1680-91	4	17
120	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. *Human Molecular Genetics*, **2015**, 24, 285-98	5.6	35
119	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16	4	20
118	Investigation of gene-environment interactions between 47 newly identified breast cancer susceptibility loci and environmental risk factors. *International Journal of Cancer*, **2015**, 136, E685-96	7.5	26
117	Data management and data analysis techniques in pharmacoepidemiological studies using a pre-planned multi-database approach: a systematic literature review. *Pharmacoepidemiology and Drug Safety*, **2015**, 24, 897-905	2.6	15
116	A polymorphism in the base excision repair gene PARP2 is associated with differential prognosis by chemotherapy among postmenopausal breast cancer patients. *BMC Cancer*, **2015**, 15, 978	4.8	6
115	Common germline polymorphisms associated with breast cancer-specific survival. *Breast Cancer Research*, **2015**, 17, 58	8.3	24
114	Large-Scale Genomic Analyses Link Reproductive Aging to Hypothalamic Signaling, Breast Cancer Susceptibility, and BRCA1-Mediated DNA Repair. *Obstetrical and Gynecological Survey*, **2015**, 70, 758-762	2.4	
113	Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis. *PLoS ONE*, **2015**, 10, e0120189	3.7	65
112	SNP-SNP interaction analysis of NF-B signaling pathway on breast cancer survival. *Oncotarget*, **2015**, 6, 37979-94	3.3	19

111	Prediction of breast cancer risk based on profiling with common genetic variants. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	324
110	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium. *Journal of Pathology: Clinical Research*, **2015**, 1, 18-32	5.3	18
109	Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. *Breast Cancer Research*, **2015**, 17, 100	8.3	35
108	Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer. *EBioMedicine*, **2015**, 2, 681-9	8.8	44
107	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. *Human Molecular Genetics*, **2015**, 24, 2966-84	5.6	36
106	Fine-scale mapping of the 5q11.2 breast cancer locus reveals at least three independent risk variants regulating MAP3K1. *American Journal of Human Genetics*, **2015**, 96, 5-20	11	59
105	The SNP rs6500843 in 16p13.3 is associated with survival specifically among chemotherapy-treated breast cancer patients. *Oncotarget*, **2015**, 6, 7390-407	3.3	14
104	Familial versus Sporadic Breast Cancer: Different Treatments for Similar Tumors?. *Advances in Breast Cancer Research*, **2015**, 04, 87-99	0.1	1
103	A large-scale assessment of two-way SNP interactions in breast cancer susceptibility using 46,450 cases and 42,461 controls from the breast cancer association consortium. *Human Molecular Genetics*, **2014**, 23, 1934-46	5.6	28
102	Mammographic screening detects low-risk tumor biology breast cancers. *Breast Cancer Research and Treatment*, **2014**, 144, 103-11	4.4	44
101	Long-term impact of the 70-gene signature on breast cancer outcome. *Breast Cancer Research and Treatment*, **2014**, 143, 587-92	4.4	45
100	Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions. *Genetic Epidemiology*, **2014**, 38, 84-93	2.6	24
99	Alcohol consumption and survival after a breast cancer diagnosis: a literature-based meta-analysis and collaborative analysis of data for 29,239 cases. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 934-45	4	29
98	FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. *British Journal of Cancer*, **2014**, 110, 1088-100	8.7	20
97	Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche. *Nature*, **2014**, 514, 92-97	50.4	401
96	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. *Nature Communications*, **2014**, 4, 4999	17.4	87
95	Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms. *Breast Cancer Research and Treatment*, **2014**, 145, 697-705	4.4	19
94	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. *Human Molecular Genetics*, **2014**, 23, 6034-46	5.6	11

93	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. *Breast Cancer Research*, **2014**, 16, R51	8.3	12
92	MicroRNA related polymorphisms and breast cancer risk. *PLoS ONE*, **2014**, 9, e109973	3.7	37
91	Genetic predisposition to in situ and invasive lobular carcinoma of the breast. *PLoS Genetics*, **2014**, 10, e1004285	6	38
90	2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. *Nature Communications*, **2014**, 5, 4051	17.4	13
89	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. *Human Molecular Genetics*, **2014**, 23, 6096-111	5.6	48
88	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. *Breast Cancer Research* , **2014**, 16, 3419	8.3	82
87	DNA mismatch repair gene MSH6 implicated in determining age at natural menopause. *Human Molecular Genetics*, **2014**, 23, 2490-7	5.6	35
86	Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy. *Cancer Biology and Therapy*, **2014**, 15, 371-9	4.6	5
85	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2014**, 16, 3416	8.3	46
84	Risk estimations and treatment decisions in early stage breast cancer: agreement among oncologists and the impact of the 70-gene signature. *European Journal of Cancer*, **2014**, 50, 1045-54	7.5	12
83	Performance of automated scoring of ER, PR, HER2, CK5/6 and EGFR in breast cancer tissue microarrays in the Breast Cancer Association Consortium **2014**, n/a-n/a		1
82	Inferior survival for young patients with contralateral compared to unilateral breast cancer: a nationwide population-based study in the Netherlands. *Breast Cancer Research and Treatment*, **2013**, 139, 811-9	4.4	21
81	Fine-scale mapping of the FGFR2 breast cancer risk locus: putative functional variants differentially bind FOXA1 and E2F1. *American Journal of Human Genetics*, **2013**, 93, 1046-60	11	80
80	Excess breast cancer risk in first degree relatives of CHEK2*1100delC positive familial breast cancer cases. *European Journal of Cancer*, **2013**, 49, 1993-9	7.5	17
79	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
78	Functional variants at the 11q13 risk locus for breast cancer regulate cyclin D1 expression through long-range enhancers. *American Journal of Human Genetics*, **2013**, 92, 489-503	11	167
77	Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome. *International Journal of Cancer*, **2013**, 132, 2044-55	7.5	9
76	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. *Nature Genetics*, **2013**, 45, 392-8, 398e1-2	36.3	327

75	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. *Nature Genetics*, **2013**, 45, 353-61, 361e1-2	36.3	813
74	Outcome of BRCA1- compared with BRCA2-associated ovarian cancer: a nationwide study in the Netherlands. *Annals of Oncology*, **2013**, 24, 2036-42	10.3	15
73	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. *PLoS Genetics*, **2013**, 9, e1003173	6	90
72	Evidence of gene-environment interactions between common breast cancer susceptibility loci and established environmental risk factors. *PLoS Genetics*, **2013**, 9, e1003284	6	112
71	Use of metformin and survival of diabetic women with breast cancer. *Current Drug Safety*, **2013**, 8, 357-63	1.4	31
70	Use of insulin and insulin analogs and risk of cancer - systematic review and meta-analysis of observational studies. *Current Drug Safety*, **2013**, 8, 333-48	1.4	77
69	Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. *Human Mutation*, **2012**, 33, 100-3	4.7	230
68	Genetic variants in TGF□1 and PAI-1 as possible risk factors for cardiovascular disease after radiotherapy for breast cancer. *Radiotherapy and Oncology*, **2012**, 102, 115-21	5.3	24
67	Genome-wide association analysis identifies three new breast cancer susceptibility loci. *Nature Genetics*, **2012**, 44, 312-8	36.3	237
66	9q31.2-rs865686 as a susceptibility locus for estrogen receptor-positive breast cancer: evidence from the Breast Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1783-91	4	17
65	Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. *PLoS ONE*, **2012**, 7, e35706	3.7	10
64	11q13 is a susceptibility locus for hormone receptor positive breast cancer. *Human Mutation*, **2012**, 33, 1123-32	4.7	33
63	19p13.1 is a triple-negative-specific breast cancer susceptibility locus. *Cancer Research*, **2012**, 72, 1795-803	13.1	93
62	PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2. *British Journal of Cancer*, **2012**, 107, 800-7	8.7	130
61	CHEK2*1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. *Journal of Clinical Oncology*, **2012**, 30, 4308-16	2.2	134
60	The role of genetic breast cancer susceptibility variants as prognostic factors. *Human Molecular Genetics*, **2012**, 21, 3926-39	5.6	75
59	Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). *PLoS ONE*, **2012**, 7, e42380	3.7	49
58	The BIO-PIN paradigm: 'access to' or 'return of' results?. *Nature Reviews Cancer*, **2011**, 11, 895; author reply 895	31.3	1

57	A role for XRCC2 gene polymorphisms in breast cancer risk and survival. *Journal of Medical Genetics*, **2011**, 48, 477-84	5.8	42
56	Association between polymorphisms of the renin-angiotensin system genes and breast cancer risk: a meta-analysis. *Breast Cancer Research and Treatment*, **2011**, 130, 561-8	4.4	31
55	Association of the germline TP53 R72P and MDM2 SNP309 variants with breast cancer survival in specific breast tumor subgroups. *Breast Cancer Research and Treatment*, **2011**, 130, 599-608	4.4	9
54	Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 2222-31	4	27
53	Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. *Journal of the National Cancer Institute*, **2011**, 103, 250-63	9.7	513
52	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. *Human Molecular Genetics*, **2011** , 20, 3289-303	5.6	140
51	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. *Nature Genetics*, **2011**, 43, 1210-4	36.3	253
50	CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women. *Journal of Medical Genetics*, **2011**, 48, 860-3	5.8	54
49	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. *Human Molecular Genetics*, **2011**, 20, 4693-706	5.6	66
48	Common breast cancer susceptibility loci are associated with triple-negative breast cancer. *Cancer Research*, **2011**, 71, 6240-9	10.1	100
47	Connective tissue: Cancer patients attitudes towards medical research using excised (tumour) tissue. *BioSocieties*, **2011**, 6, 466-486	1.5	8
46	An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. *Annals of Oncology*, **2011**, 22, 1561-1570	10.3	131
45	Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. *British Journal of Cancer*, **2011**, 105, 1934-9	8.7	4
44	Independent prognostic value of screen detection in invasive breast cancer. *Journal of the National Cancer Institute*, **2011**, 103, 585-97	9.7	83
43	Annexin A1 regulates TGF-beta signaling and promotes metastasis formation of basal-like breast cancer cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2010**, 107, 6340-5	11.5	151
42	Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 2143-51	4	31
41	The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. *Annals of Oncology*, **2010**, 21, 717-722	10.3	115
40	Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies. *PLoS Medicine*, **2010**, 7, e1000279	11.6	616

39	Tumour tissue: who is in control?. *Lancet Oncology, The*, **2010**, 11, 9-11	21.7	5
38	A trial of consent procedures for future research with clinically derived biological samples. *British Journal of Cancer*, **2009**, 101, 1505-12	8.7	31
37	Opt-out plus, the patients' choice: preferences of cancer patients concerning information and consent regimen for future research with biological samples archived in the context of treatment. *Journal of Clinical Pathology*, **2009**, 62, 275-8	3.9	26
36	Association of ESR1 gene tagging SNPs with breast cancer risk. *Human Molecular Genetics*, **2009**, 18, 1131-9	5.9	75
35	Family history, genetic testing, and clinical risk prediction: pooled analysis of CHEK2 1100delC in 1,828 bilateral breast cancers and 7,030 controls. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 230-4	4	44
34	The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. *Breast Cancer Research and Treatment*, **2009**, 116, 295-302	4.4	222
33	Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. *Nature Genetics*, **2009**, 41, 585-90	36.3	393
32	Obtaining 'fresh' consent for genetic research with biological samples archived 10 years ago. *European Journal of Cancer*, **2009**, 45, 1168-1174	7.5	27
31	Regulatory aspects of genetic research with residual human tissue: effective and efficient data coding. *European Journal of Cancer*, **2009**, 45, 2376-82	7.5	9
30	Five polymorphisms and breast cancer risk: results from the Breast Cancer Association Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 1610-6	4	53
29	Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients. *Breast Cancer Research*, **2009**, 11, R89	8.3	31
28	Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study. *Lancet Oncology, The*, **2009**, 10, 1070-6	21.7	133
27	Predicting response to alkylating chemotherapy in breast cancer patients using array comparative genomic hybridization. **2009**,		6
26	ATBF1 and NQO1 as candidate targets for allelic loss at chromosome arm 16q in breast cancer: absence of somatic ATBF1 mutations and no role for the C609T NQO1 polymorphism. *BMC Cancer*, **2008**, 8, 105	4.8	17
25	An information-theoretic analysis of genetics, gender and age in cancer patients. *PLoS ONE*, **2008**, 3, e1951	3.7	16
24	The spectrum of ATM missense variants and their contribution to contralateral breast cancer. *Breast Cancer Research and Treatment*, **2008**, 107, 243-8	4.4	27
23	Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. *Cancer Research*, **2007**, 67, 9584-90	10.1	69
22	A common coding variant in CASP8 is associated with breast cancer risk. *Nature Genetics*, **2007**, 39, 352-8	36.3	557

21	The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. *European Journal of Human Genetics*, **2007**, 15, 110-4	5.3	85
20	Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. *Journal of Clinical Oncology*, **2007**, 25, 64-9	2.2	92
19	Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. *Breast Cancer Research*, **2007**, 9, R26	8.3	60
18	Breast tumors induced by high-dose radiation display similar genetic profiles. *Breast Cancer Research*, **2005**, 7, 1	8.3	78
17	Genetic determinants of breast cancer characteristics and outcome in women under 50 years of age. *Breast Cancer Research*, **2005**, 7, 1	8.3	78
16	Clinical outcome for BRCA1 and BRCA2 mutation carriers after contralateral prophylactic mastectomy. *Breast Cancer Research*, **2005**, 7, 1	8.3	78
15	Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. *British Journal of Cancer*, **2005**, 93, 287-92	8.7	269
14	Mental and psychomotor development in Indonesian infants of mothers supplemented with vitamin A in addition to iron during pregnancy. *British Journal of Nutrition*, **2004**, 91, 279-86	3.6	31
13	Nutritional status and linear growth of Indonesian infants in west java are determined more by prenatal environment than by postnatal factors. *Journal of Nutrition*, **2002**, 132, 2202-7	4.1	43
12	Determinants of weight and length of Indonesian neonates. *European Journal of Clinical Nutrition*, **2002**, 56, 947-51	5.2	19
11	Randomised double-blind trial of the effect of vitamin A supplementation of Indonesian pregnant women on morbidity and growth of their infants during the first year of life. *European Journal of Clinical Nutrition*, **2002**, 56, 338-46	5.2	27
10	Weekly supplementation with iron and vitamin A during pregnancy increases hemoglobin concentration but decreases serum ferritin concentration in Indonesian pregnant women. *Journal of Nutrition*, **2001**, 131, 85-90	4.1	76
9	Vitamin A and iron supplementation of Indonesian pregnant women benefits vitamin A status of their infants. *British Journal of Nutrition*, **2001**, 86, 607-15	3.6	30
8	Weekly vitamin A and iron supplementation during pregnancy increases vitamin A concentration of breast milk but not iron status in Indonesian lactating women. *Journal of Nutrition*, **2001**, 131, 2664-9	4.1	35
7	Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1, updates to tumour pathology and cancer incidences		1
6	Common variants in breast cancer risk loci predispose to distinct tumor subtypes		1
5	Prospective Evaluation of a Breast Cancer Risk Model Integrating Classical Risk Factors and Polygenic Risk in 15 Cohorts from Six Countries		2
4	Combining genome-wide studies of breast, prostate, ovarian and endometrial cancers maps cross-cancer susceptibility loci and identifies new genetic associations		2

3	Assessment of Polygenic Architecture and Risk Prediction based on Common Variants Across Fourteen Cancers	1
2	Genomic analyses for age at menarche identify 389 independent signals and indicate BMI-independent effects of puberty timing on cancer susceptibility	1
1	Genomic profiling defines variable clonal relatedness between invasive breast cancer and primary ductal carcinoma in situ	1